Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial.

OBJECTIVE--To study the effect of epoprostenol (prostacyclin, PGI2) given before, during, and for 36 h after coronary angioplasty on restenosis at six months and to evaluate the transcardiac gradient of platelet aggregation before and after percutaneous transluminal coronary angioplasty (PTCA) in tr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gershlick, A. H., Spriggins, D., Davies, S. W., Syndercombe Court, Y. D., Timmins, J., Timmis, A. D., Rothman, M. T., Layton, C., Balcon, R.
Formato: Artigo
Idioma:Inglês
Publicado em: 1994
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC483601/
https://ncbi.nlm.nih.gov/pubmed/8297699
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados